Thanksgiving break didn't slow down reviewers at the US FDA, as the agency came roaring out of the holiday with a batch of novel approvals.
Nods to Astellas Pharma Inc.'s Xospata (gilteritinib)and Catalyst Pharmaceuticals Inc.'s Firdapse (amifampridine) brought FDA's 2018 new molecular entity...








